On October 10, Illumina rose 5.19% in regular trading, trading at $278.29 per share, with turnover of $387 million.

The advance follows the company's recent launch of SpliceAI2, a new AI genomic model designed to support rare disease research. The model identified 17% more disease-relevant variants than other splicing models on a test dataset and is accessible through BioInsight applications. The launch strengthens Illumina's positioning in AI-driven multi-omics.

Separately, RBC Capital Markets raised its price target on Illumina to $310 from $230 and maintained an outperform rating, citing durable mid-teens clinical sequencing revenue growth and an expected incremental 1 to 2 percentage point contribution from BioInsight in fiscal 2027. Guggenheim, Leerink Partners, Piper Sandler, and Evercore ISI also lifted their targets, reflecting broadened analyst confidence. Barclays raised its target to $200 from $160 but kept an underweight rating.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function, serving genomic research centers, hospitals, pharmaceutical firms, and consumer genomics companies through direct and distributor channels worldwide.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)